Emily Gibbons, Gilead Sciences: the lenacapavir partnership

About this episode

Emily Gibbons discusses the partnership between Gilead Sciences, the Trump administration, and the Global Fund to launch lenacapavir for HIV prevention in Africa.

Gilead Sciences, the Trump administration, and the Global Fund have joined in partnership to bring lenacapavir, the new twice-yearly injectable prevention tool against HIV/AIDS, to two million persons at-risk in ten African countries in three years. Emily Gibbons, Gilead Sciences, explains the back story—the determined work of the previous two and a half years to plan an effective launch that would have speed, support from communities, access to affordable volumes of the medicine, and implementation to deliver. She also speaks to the challenges ahead to see lenacapavir reach a meaningful scale to drive HIV infections down, especially among the most vulnerable populations.

People in this episode

Guest: Emily Gibbons

Topics covered

• HIV/AIDS
• healthcare
• partnerships
• global health

Keywords

• lenacapavir
• Gilead Sciences
• Global Fund
• HIV prevention
• Africa

Mentioned in this episode

Products: lenacapavir

More episodes of Take as Directed

• Dr. Jeffrey Gold, President of the University of Nebraska: “Containing outbreaks is always in our national interest.” · June 11, 2026 · 39 min
• Professor Rebecca Katz, Georgetown University: the Health Security Operations Center during the FIFA World Cup · May 21, 2026 · 31 min
• Professor Paul Spiegel, Johns Hopkins University: the release of the Lancet Commission report on health, conflict and forced displacement · May 20, 2026 · 45 min
• Priya Basu, the Pandemic Fund: "Countries are not sitting on the fence. They are lining up." · May 8, 2026 · 36 min
• A Conversation with Dr. Sania Nishtar, CEO of Gavi, the Vaccine Alliance | The Futures Summit · May 6, 2026 · 48 min
• The Lenacapavir Partnership and the Evolution of U.S. Foreign Assistance | The Futures Summit · May 5, 2026 · 1h 13m